← All countries · Americas
87%
MCV1
2025 · WHO/UNICEF estimate
86%
DTP3
2025 · WHO/UNICEF estimate
87%
IPV complete
2025 · WHO/UNICEF estimate
86%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
114
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 87%2025 · WHO/UNICEF estimate | 87.1% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 88%2025 · WHO/UNICEF estimate | 87.8% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 86%2025 · WHO/UNICEF estimate | 86.1% | B · good | |
| IPV1First dose of inactivated polio vaccine | 88%2025 · WHO/UNICEF estimate | 87.6% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 87%2025 · WHO/UNICEF estimate | 87.4% | D · poor | |
| MCV1First dose of measles-containing vaccine | 87%2025 · WHO/UNICEF estimate | 86.8% | B · good | |
| MCV2Second dose of measles-containing vaccine | 84%2025 · WHO/UNICEF estimate | 84.4% | B · good | |
| RCV1First dose of rubella-containing vaccine | 87%2025 · WHO/UNICEF estimate | 86.8% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 86%2025 · WHO/UNICEF estimate | 87% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 78%2025 · WHO/UNICEF estimate | 78.1% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 86%2025 · WHO/UNICEF estimate | 87% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 87.9%2025 · Administrative (country-reported) | 87.9% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 86%2025 · WHO/UNICEF estimate | 86.1% | B · good | |
| RotaCRotavirus vaccine, complete series | 87%2025 · WHO/UNICEF estimate | 87.4% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | 100%2024 · Administrative (country-reported) | 100% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 99%2024 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 73%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 73%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 2112025 | 19.2per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 1142025 | 10.4per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 52025 | 0.5per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Invasive meningococcal disease all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (72 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B-Y1 | General/routine | Recien Nacidos con peso mayor de 2,500 gramos y menores de 1 año |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M4 | Risk group(s) | Población de 4 meses a 4 años que presentaron reacción alérgica al componente pertussis de la Pentavalente |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | Población de 4 meses a 4 años que presentaron reacción alérgica al componente pertussis de la Pentavalente |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 4 | M18 | Risk group(s) | Población de 4 meses a 4 años que presentaron reacción alérgica al componente pertussis de la Pentavalente |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4 | Risk group(s) | Población de 4 meses a 4 años que presentaron reacción alérgica al componente pertussis de la Pentavalente |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | 1 a 4 años los refuerzos |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4 | General/routine | 1 a 4 años los refuerzos |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | Menor de 1 año |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | Menor de 1 año |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | Menor de 1 año |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | 1st contact | Health workers | Tradbajadores de Salud |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6 | Health workers | Tradbajadores de Salud |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Y1 | General/routine | Población de 1 año |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 4 | +Y1 | Health workers | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 4 | +Y1 | Risk group(s) | Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc… |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Primeras 24 horas de nacido |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11-Y15 | HPV for females only | Niñas de 11 a 15 años |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M23 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | Menor de 1 año y niños inmunocomprometidos menor de 2 años |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | Menor de 1 año y niños inmunocomprometidos menor de 2 años |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | Risk group(s) | Menor de 1 año y niños inmunocomprometidos menor de 2 años |
| IPVIPV (Inactivated polio vaccine) | 4 | M18 | Risk group(s) | Menor de 1 año y niños inmunocomprometidos menor de 2 años |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Población de 1 año |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | >=Y5 | Risk group(s) | Vacuna contra Sarampión, Rubéola y Parotiditis(Cepa Jeryl Lynn) - Grupos en riesgo mayores de 5 años sin antecedente de haber padecido la enfermedad o de no haber sido vacunado. |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | Población de 1 año |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | Menor de 2 años |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | Menor de 2 años |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | Menor de 1 año |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | Menor de 1 año |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | Menor de 1 año |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | Menor de 1 año |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | Menor de 1 año |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | 1st contact | Health workers | Embarazadas 26 a 37 SG y personal de salud durante brotes en una región |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | 1st contact | Pregnant women | Embarazadas 26 a 37 SG y personal de salud durante brotes en una región |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Health workers | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Risk group(s) | otros grupos de riesgo esquema de 3 dosis y un refuerzo cada 10 años |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Health workers | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Risk group(s) | otros grupos de riesgo esquema de 3 dosis y un refuerzo cada 10 años |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Health workers | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Risk group(s) | otros grupos de riesgo esquema de 3 dosis y un refuerzo cada 10 años |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Health workers | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Health workers | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | Embarazadas, trabajadores de salud etc |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y11 | General/routine | Dosis única 11 años |
| VARICELLAVaricella vaccine | 1 | M15 | General/routine | Niños de 15 meses |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| VITAMINAVitamin A supplements | 5 | M30 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| VITAMINAVitamin A supplements | 6 | M36 | General/routine | Se suplementa a menor de 5 años. A partir de los 6 meses, y luego cada 6 meses |
| YFYF (Yellow fever) vaccine | 1 | Y1-Y59 | Travellers | Aje1 a 59 años viaros a zona endémica por Fiebre A |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.